senior man on the beach

Colorectal Cancer 

Labcorp Oncology offers a comprehensive test menu to support you in the diagnosis and treatment of patients with colorectal cancer throughout their continuum of care, from early screening and diagnostics through treatment and follow-up. 

DNA icon

Genetic Risk Evaluation

Germline Testing

VistaSeq® Hereditary Cancer Panels

Provides an assessment of genetic mutations known to be associated with hereditary cancer syndromes.

Learn more about VistaSeq® Hereditary Cancer Panels

Germline Testing

Lynch Syndrome Germline Testing

Full gene sequencing and deletion/duplication analysis to confirm a clinical diagnosis of Lynch syndrome. Lynch syndrome accounts for about 3% of all colorectal cancer (CRC) cases.2,3

Learn more about Lynch Syndrome Germline Testing

Clipboard Icon

Screening

Screening

Septin 9 Gene Methylation Detection

Qualitative in vitro diagnostic method for the detection of methylated Septin 9 DNA in plasma. The methylated form of Septin 9 DNA has been associated with the occurrence of colorectal cancer.4

Learn more about Septin 9 Gene Methylation Detection

Screening

Fecal Occult Blood Immunoassay

Qualitative detection of fecal occult blood. This test is intended only for the detection of human hemoglobin in fecal specimens and is designed for preliminary colorectal cancer screening. A positive result should be followed up with additional diagnostic procedures.5

Learn more about Fecal Occult Blood Immunoassay

Diagnostic Icon

Diagnostic

Diagnostic

Complex Tumor Analysis by IHC

Our extensive antibody library and team of pathologists experienced in varying sub-specialties enable us to provide a differential diagnostic analysis in even the most difficult cases.

Learn more about Complex Tumor Analysis by IHC

Diagnostic

Comprehensive Lynch Syndrome Tumor Testing

Tumor testing can reveal whether the colorectal cancer is caused by the genes related to Lynch syndrome. Tumor tests include immunohistochemistry and/or molecular analysis. Positive/absent results indicate a malfunction in the genes connected to Lynch syndrome.

Learn more about Comprehensive Lynch Syndrome Tumor Testing

Predictive icon

Predictive

Predictive tests for clinical management and treatment decision-making

TestDetectsTherapy
KRAS mutation analysis6,7Mutations in the KRAS gene (exons 2, 3, and 4)Cetuximab Panitumumab
NRAS mutation analysis8,9Mutations in the NRAS gene (exons 2, 3, and 4)Cetuximab Panitumumab
BRAF mutation analysis10Mutations in the BRAF geneCetuximab Panitumumab
HER2 by IHC or FISH11HER2 overexpression or amplificationAnti-HER2 therapy
MSI by PCR or mismatch repair (MMR) proteins by IHC 12Microsatellite instabilityPembrolizumab
DPD 5-FU toxicity analysis13Mutation in the DPD gene (IVS14+1G>A mutation)5-FU-based chemotherapy
UGT1A114,15 (Invader® Technology)Polymorphism UGT1A1*28Irinotecan
OmniSeq INSIGHTSM NGS genomic and immune profilingIncludes PD-L1 IHC, DNA and RNA sequencing (523 genes), MSI, TMB*, fusion analysis including NTRK, and immune gene profilingTargeted therapies and immunotherapies

*TMB - tumor mutational burden

Calendar Icon

Monitoring

Monitoring

Cancer Antigen 19-9

For the quantitative determination of CA 19-9 tumor-associated antigen in serum or plasma of patients with colorectal cancer to monitor disease process.16

Learn more about Cancer Antigen 19-9

Monitoring

Carcinoembryonic Antigen (CEA)

For the in vitro quantitative determination of carcinoembryonic antigen in human serum and plasma. The CEA assay is indicated for serial measurement of CEA to aid in the management of cancer patients.17

Learn more about Carcinoembryonic Antigen (CEA)

References